$25 HIV Cure? Researchers Detail Low-Cost Drug Potential

The high cost of HIV treatment ⁣takes center stage as we examine lenacapavir’s crucial role, a new prevention ⁤drug creating waves in the medical landscape. The article delves into the pricing strategies⁤ of pharmaceutical giant Gilead, revealing the potential for immense profit margins and the resulting debates surrounding patient access and global affordability. Researchers explore the complex equation of balancing innovation with equitable healthcare.The secondary keyword focuses on this drug named lenacapavir and its impact on the future of HIV treatment. News Directory 3 brings you this critical analysis of lenacapavir. Uncover the forces shaping the future of HIV treatment; discover what’s next in the ongoing fight ⁢against this global health crisis.